Glucose-lowering therapies linked to reduced risk for CV events in type 2 diabetes, MASLD

Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists were associated with lower risk for cardiovascular events in type 2 diabetes, with or without metabolic dysfunction-associated steatotic liver disease.
“Glucose-lowering medications, such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA), have shown cardiorenal benefits beyond blood glucose control,” Sungho Bea, PharmD, of the School of Pharmacy at Sungkyunkwan University, and colleagues wrote in JAMA Network Open. “Moreover,

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart